Antenatal care: (consultation)

Antenatal care (partial update) - Consultation

The clinical practice guideline on Antenatal care for use in the NHS in England and Wales is being partially updated by NICE. Please see background information below for further information on this. Registered stakeholders for this guideline are invited to comment on the provisional updated recommendations via this website.

Although individuals and organisations not registered as stakeholders are able to comment, we recommend that you contact the registered stakeholder organisation that most closely represents your interests and pass your comments to them. We work closely with stakeholder organisations and take their views very seriously.

Note that the provisional updated recommendations presented here do not constitute the Institute's formal guidance on this topic. The recommendations are provisional and may change after consultation.

Consultation dates: 4 September - 29 October 2007

Consultation documents: (All documents can be found at the end of the page)

  • Full guideline plus appendices (including evidence tables and references)
  • Algorithm
  • NICE guideline
  • Comments proforma

The full version describes the evidence and views that have been considered, and sets out the provisional updated recommendations that have been developed. New or amended sections are indicated by a green bar in the right-hand side of the page.

The (NICE) short version presents the provisional recommendations only with some brief supporting information.  New or amended recommendations are indicated by a green bar in the right-hand side of the page, flagged [NEW].

Please note that a separate consultation will follow on chapter 14 of this guideline between 9 October and 3 December 2007. Further information can be found here.

Background to the update


The original antenatal care guideline was published by NICE in 2003. Since then a number of important pieces of evidence have become available, particularly concerning gestational diabetes, haemoglobinopathy and ultrasound, so that the update has been initiated earlier than planned. This early update has also provided an opportunity to look at a number of aspects of antenatal care and these include:

  • The development of a method to assess women for whom additional care is necessary (the 'assessment tool')
  • Information giving to women
  • Lifestyle:
  • vitamin D supplementation
  • alcohol use
  • Screening for the baby:
  • use of ultrasound for gestational age assessment and screening for fetal abnormalities
  • methods for determining normal fetal growth
  • haemoglobinopathy screening
  • Screening for the mother:
  • gestational diabetes
  • pre-eclampsia and preterm labour
  • chlamydia.

Points to consider in the consultation:

Please comment on new or amended recommendations only. Recommendations that are unchanged from the original guideline are not being consulted on. 

Key recommendations have been selected from the partial update of the guideline.

Full version

  • points or areas that are not covered, but which appear to fall within the scope of the guideline update
  • potential inconsistencies or any disagreement with the Guideline Development Groups interpretation of the evidence
  • the practical value of the provisional updated recommendations.

NICE version

  • Issues of style and format; for example, stakeholders may feel that the information could be made more readable and easy to follow.

How to submit your comments:

  • Please use the comments proforma and return by email to ANC@nice.org.ukor on a disk to:

    Adelle McGill
    Project Manager - CCP
    National Institute for Health and Clinical Excellence
    MidCity Place
    71 High Holborn
    London
    WC1V 6NA

The Institute is unable to accept:

  • Comments relating to recommendations that have not been updated
  • More than one response per stakeholder organisation
  • Comments received after the consultation deadline
  • Comments that are not on the correct proforma
  • Confidential information or other material that you would not wish to be made public
  • Personal medical information about yourself or another person from which your or the person's identity could be ascertained.

What will happen to your comments:

  • All comments (with the exception of personal, individual comments) will be sent to the developers at the end of the consultation
  • Comment from registered stakeholders ONLY will be formally responded to by the developers and posted on the NICE website after the final guideline is published
  • Personal, individual comments will be forwarded to the Patient and Public Involvement Programme for NICE, who will consider them when making their response.

Acknowledgement of comments:

You should receive an automated acknowledgement from the email box when you email your comments. If you do not receive this acknowledgement, please contact the relevant Guidelines Coordinator to ensure your comments have been safely received.


Anticipated publication date: March 2008

Further  information

This page was last updated: 30 March 2010